The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug an...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-02-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/24/4/809 |
| id |
doaj-223bef44afd74873b21b3fe612e077f6 |
|---|---|
| record_format |
Article |
| spelling |
doaj-223bef44afd74873b21b3fe612e077f62020-11-24T21:16:00ZengMDPI AGMolecules1420-30492019-02-0124480910.3390/molecules24040809molecules24040809The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of MoleculesBeatriz G. de la Torre0Fernando Albericio1KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South AfricaSchool of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South AfricaThe Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017. Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chemical perspective. The classification has been carried out on the basis of the chemical structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small molecules.https://www.mdpi.com/1420-3049/24/4/809antibodiesAPIbiologicschemical entitiesdrug discoveryfluorine based drugsnatural productsoligonucleotidespeptideTIDESsmall molecules |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Beatriz G. de la Torre Fernando Albericio |
| spellingShingle |
Beatriz G. de la Torre Fernando Albericio The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules Molecules antibodies API biologics chemical entities drug discovery fluorine based drugs natural products oligonucleotides peptide TIDES small molecules |
| author_facet |
Beatriz G. de la Torre Fernando Albericio |
| author_sort |
Beatriz G. de la Torre |
| title |
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules |
| title_short |
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules |
| title_full |
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules |
| title_fullStr |
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules |
| title_full_unstemmed |
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules |
| title_sort |
pharmaceutical industry in 2018. an analysis of fda drug approvals from the perspective of molecules |
| publisher |
MDPI AG |
| series |
Molecules |
| issn |
1420-3049 |
| publishDate |
2019-02-01 |
| description |
The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017. Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chemical perspective. The classification has been carried out on the basis of the chemical structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small molecules. |
| topic |
antibodies API biologics chemical entities drug discovery fluorine based drugs natural products oligonucleotides peptide TIDES small molecules |
| url |
https://www.mdpi.com/1420-3049/24/4/809 |
| work_keys_str_mv |
AT beatrizgdelatorre thepharmaceuticalindustryin2018ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules AT fernandoalbericio thepharmaceuticalindustryin2018ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules AT beatrizgdelatorre pharmaceuticalindustryin2018ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules AT fernandoalbericio pharmaceuticalindustryin2018ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules |
| _version_ |
1716743739330789376 |